Search clinical trials for: KA2507

Total 4 results

Karus Therapeutics Limited
University College, London

Withdrawn

A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

Biliary Tract Cancer

United Kingdom
Karus Therapeutics Limited

Completed

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (HDAC6i)

Solid Tumor, Adult

United States
Karus Therapeutics Limited

Completed

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Advanced Solid Tumor

China

3

Subscribe